Non-Small Cell Lung Cancer (NSCLC) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The non-small cell lung cancer (NSCLC) market reached a value of USD 12.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 25.0 Billion by 2035, exhibiting a growth rate (CAGR) of 6.80% during 2025-2035.

The Non-Small Cell Lung Cancer (NSCLC) Market has been comprehensively analyzed in IMARC’s new report titled “Non-Small Cell Lung Cancer (NSCLC) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035”. Non-small cell lung cancer (NSCLC) is a form of oncology disease in which malignant (cancer) cells form in the lung tissues. It can be categorized into squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Other less-known types of non-small cell lung cancer are adenosquamous carcinoma, sarcomatoid carcinoma, salivary gland carcinoma, carcinoid tumor, and unclassified carcinoma. The major symptoms of non-small lung cancer are continuous cough and shortness of breath. In addition to this, chest discomfort or pain, wheezing, blood in sputum, hoarseness, loss of appetite, weight loss, tiredness, and trouble swallowing are the other common symptoms experienced by patients suffering from non-small cell lung cancer (NSCLC). Non-small cell lung cancer is diagnosed and staged using pulmonary examination tests, which are carried out simultaneously. Physical exams, laboratory tests, chest X-rays, CT scans (CAT scans), sputum cytology, and thoracentesis are the common tests and procedures performed to detect non-small cell lung cancer (NSCLC) among patients. Some treatment options for non-small cell lung cancer (NSCLC) are bronchoscopy, thoracoscopy, mediastinoscopy, lymph node biopsy, etc.

The increasing incidences of respiratory disorders on account of the deteriorating air quality, unhealthy lifestyle preferences, and high smoking rates among the masses are primarily driving the non-small cell lung cancer market. In addition to this, the expanding geriatric population, who are more prone to develop acute respiratory illnesses, is also bolstering the market growth. Moreover, the rising demand for targeted therapies owing to improved patient outcomes is further creating a positive outlook for the market. These treatments aim to selectively target cancer cells by adhering to or obstructing targets that are present on their surfaces. Besides this, the widespread adoption of radiation therapy combined with chemotherapy to treat patients with locally advanced unresectable disease is also acting as a significant growth-inducing factor. Several other factors, including the continuous upgradation of the existing healthcare infrastructures and the introduction of advanced variants with enhanced efficacy and effectiveness of treatment, are expected to drive the non-small cell lung cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the non-small cell lung cancer (NSCLC) market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for non-small cell lung cancer (NSCLC) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the non-small cell lung cancer (NSCLC) market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, Current and Future Epidemiology Scenario
• Historical, Current and Future Performance of the Non-Small Cell Lung Cancer (NSCLC) Market
• Historical, Current and Future Performance of Various Therapeutic Categories in the Non-Small Cell Lung Cancer (NSCLC) Market
• Sales of Various Drugs Across the Non-Small Cell Lung Cancer (NSCLC) Market
• Reimbursement Scenario in the Non-Small Cell Lung Cancer (NSCLC) Market
• In-Market and Pipeline Drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Non-Small Cell Lung Cancer (NSCLC) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the non-small cell lung cancer (NSCLC) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the non-small cell lung cancer (NSCLC) across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the non-small cell lung cancer (NSCLC) across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of non-small cell lung cancer (NSCLC) across the seven major markets?
• What is the number of incident cases (2019-2035) of non-small cell lung cancer (NSCLC) by age across the seven major markets?
• What is the number of incident cases (2019-2035) of non-small cell lung cancer (NSCLC) by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of non-small cell lung cancer (NSCLC) by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with non-small cell lung cancer (NSCLC) across the seven major markets?
• What is the size of the non-small cell lung cancer (NSCLC) patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend non-small cell lung cancer (NSCLC) of?
• What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for non-small cell lung cancer (NSCLC) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the non-small cell lung cancer (NSCLC) market?
• What are the key regulatory events related to the non-small cell lung cancer (NSCLC) market?
• What is the structure of clinical trial landscape by status related to the non-small cell lung cancer (NSCLC) market?
• What is the structure of clinical trial landscape by phase related to the non-small cell lung cancer (NSCLC) market?
• What is the structure of clinical trial landscape by route of administration related to the non-small cell lung cancer (NSCLC) market?